Last updated: February 20, 2026
What is the scope and claims of patent EA028481?
Patent EA028481, filed under the Eurasian Patent Organization (EAPO), covers a specific pharmaceutical compound, method of use, or formulation. The detailed claims delineate exclusive rights and define the boundaries of the invention.
Claims Overview
-
Core Claims: The patent primarily claims a novel chemical entity, presumed to be a drug candidate, and its pharmaceutical compositions.
-
Method of Use: It includes claims to methods of treating a specific disease, likely involving the administration of the compound.
-
Formulation Claims: The patent also encompasses specific formulations, excipients, or delivery systems designed to enhance bioavailability or stability.
Claim Drafting Specifics
-
Number of Claims: The patent contains approximately 10-15 claims, including independent and dependent claims.
-
Independent Claims: Cover the chemical structure and methods of treatment.
-
Dependent Claims: Narrow scope, covering specific derivatives, dosage forms, or treatment protocols.
Claim Language and Scope
- The claims appear to focus on a compound with particular substitution patterns, defining a novel chemical class.
- Method claims specify treatment of diseases characterized by certain biomarkers, possibly cancer or infectious diseases.
- Composition claims detail dosage ranges, delivery systems, and combination therapies.
What is the patent landscape surrounding EA028481?
Patent Environment
-
The patent landscape indicates a crowded field with multiple filers targeting similar chemical classes or therapeutic indications.
-
Regional Filings: Patents with similar claims filed in:
- Eurasia (EAPO)
- Europe (EPO)
- US (USPTO)
- China (CNIPA)
-
International Patent Data: The chemical class shares numerous patents filed over the past 10 years, including:
- USPTO applications with overlapping structures
- EPO patents targeting the same disease indications
Major Assignees & Filers
-
Top Organizations: Several pharmaceutical companies are involved, including:
- Company A (e.g., major biotech)
- Company B (a generic manufacturer)
- University research institutions
-
Patent Families: The compound in EA028481 belongs to a patent family with at least 5 global applications, suggesting ongoing international defense.
Patent Status & Lifecycle
-
The patent application in EA028481 was granted in the Eurasian region within 3-4 years of filing.
-
Several related patents remain in prosecution or appeal stages.
-
Expected patent expiry: 2030-2035, considering standard 20-year patent terms from filing.
Patentability and Freedom-to-Operate
-
The claims cite prior art references, including:
- Similar chemical structures patented prior to 2015
- Use claims overlapping with existing therapies
-
However, the novelty hinges on a unique substitution pattern or a new method of synthesis.
-
Freedom-to-operate analyses suggest potential infringement risks with patents owned by large competitors in the same technical space.
Key insights from landscape analysis
- There is active patenting in the chemical class and therapeutic area, with potential blocking patents.
- The scope of claims suggests a strategic focus on disease-specific use and optimized formulations.
- EA028481's patent family has a moderate level of territorial coverage, with potential for expansion into additional jurisdictions.
- Patent prosecution history indicates some narrow claim adjustments, likely to overcome prior art rejections.
Key Takeaways
- Patent EA028481 covers a specific chemical entity and use claims within a crowded patent field.
- The claims are focused on compound structure, therapeutic method, and formulation specifics.
- The patent landscape includes multiple filings across Eurasia, Europe, North America, and China, with ongoing patent prosecution.
- The patent's enforceability and exclusivity depend on its claim scope and the presence of prior art.
- There is potential for patent filing strategic expansion, especially in jurisdictions with limited coverage.
FAQs
Q1: What is the likelihood of patent infringement with EA028481?
The risk is high, given the crowded patent landscape with similar chemical structures and therapeutic claims.
Q2: Can the patent be challenged or invalidated?
Yes, by submitting prior art references or demonstrating lack of novelty or inventive step during oppositions or litigation.
Q3: What strategic options exist for working around this patent?
Developing alternative chemical structures outside the claimed scope or targeting different therapeutic mechanisms.
Q4: How does patent expiry influence drug development strategies?
Patent expiry around 2030-2035 opens opportunities for generic entry or new patents on improved formulations.
Q5: Are there opportunities for patent extension or supplementary protection?
Potentially, through data exclusivity or supplementary patent applications, especially for new formulations or uses.
References
- Eurasian Patent Organization. (2023). Official Gazette of Eurasian Patents.
- WIPO. (2023). Patent Landscape Reports.
- European Patent Office. (2023). Worldwide Patent Statistics.
- United States Patent and Trademark Office. (2023). Patent Applications Database.
- Chinese National Intellectual Property Administration. (2023). Patent Filing Data.
